Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

Table 4 International Myeloma Working Group Consensus guidelines and recommendations on mobilization in malignant lymphoma[20]

Strategy	Recommendations
Mobilization
G-CSF alone	Limit use to patients
	Treated with ≤ 1 line of therapy
	Never exposed to melphalan
	Received ≤ 4 cycles of lenalidomide
	Use doses from 10-16 μg/kg per day
	Monitor PB CD34+ count
Chemomobilization + G-CSF	Limit to patients who have not adequately responded to salvage therapy
Plerixafor	Suitable for all patients particularly if goals include
	Highest cell yield obtainable
	Fewer apheresis sessions
Remobilization
Plerixafor	P + G-CSF or P + CM + G-CSF
Chemomobilization	Acceptable in patients who failed cytokine mobilization
Bone marrow harvest	Use as third-line option in patients in whom ASCT is compelling

PBCD34⁺: Peripheral blood CD34⁺ cells; P + G-CSF: Plerixafor + granulocyte colony stimulating factor; P + CM + G-CSF: Plerixafor + chemomobilization + granulocyte colony stimulating factor.